*9 adult RA patients received low-dose IL-2 plus Actemra (tocilizumab) *26 adult RA patients received IL-2 without Actemra *15 adult RA patients got neither *We endorse low-dose IL-2 plus Actemra for treating RA patients with high effector T-cell levels ht
50 active RA pts RCT Rx w. either low dose IL-2(n=26), IL-2+TCZ (9) or control (15). All improved clinically by DAS28-ESR, but IL-2 Rx pts had signif proliferation of Tregs, w. decr inTh1, Th2, & Th17 cells. TREG #s correlated w/ ESR drop (r=0.54) ht
The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis https://t.co/LiMexGV26z #FrontImmunol